(f) if so, the details tehreof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMCALS AND FERTILIZERS (SHRI CHNTA MOHAN): To the extent information available, the production of bulk drug Dipyridamol has not been started in the country.

(b) The present ceiling price of formulations which have been fixed on 9th July, 1992 are based on the current weighted average landed cost of DGHS;

(c) and (d) Prima facie there appears to be no case of overinvoicing against M/s. German Remedies.

(e) and (f) The prices of formulations are fixed on the basis of weighted average landed cost of DGHS from time to time.

Assessment of liability of M|s. Merind by special team

4587. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to state:

(a) on what basis the special team assessed the liabjlity of M|s. Merind at Rs. 138.79 lakhs upto 31st December, 1993 in respect of Dexamethasone and its salts:

(b) what are the basis on which the liabiljty was revised to Rs. 781.50 lakhs for the same period;

(c) what are the details of calculations of both the assessments and how did Government tolerate suppression of liabilities by the special team;

(d) whether it is a fact that the company have also shown their liability upto 31st December, 1983 in their annual accounts and what was the amount indicated;

(e) whether it is a fact that company has not paid the dues so far; and

(f) if so, the action taken thereon?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (f) The liability of M/s. Merind in respect of overcharging of Dexamethason and its formulations was assessed as Rs. 138.79 lacs by the Special Team for the period upto December, 1983. On receipt of complaint alleging irdegularities in the computations made by the Special Team, it was decided in 1989 to review their recommendations. Accordingly, revised tentative liability has been computed as Rs. 781.58 lacs for the period upto December, 1983 and Rs. 1610.14 lacs for the period after December, 1983.

To the extent information is available, M|s. Merind had shown its liability under DPEA as Rs. 468.07 lacs in its Annual Accounts for the year ending 31.12.1983. M|s. Merind has not deposited any amount into DPEA so far. The company is seeking personal hearing against their tentative liability and it has been proposed to give hearing to the company very shortly.

Complaints of overcharging prices of bulk drugs

4588. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) what are the names of bulk drugs in respect of which complaints of over-charging of prices have been received during the year 1992;

(b) what is the actual position against each of these complaints and what action has been taken in each;

(c) whether it is a fact that Vitamin C, Metronidazole, INH, Ampicillin, Cloxacillin, Amoxicillin, Cephalexin, Nifidipine, Chloroquin etc. are all being overcharged on one pretext or the other;

(d) whether it is a fact that action gainst none of the producers have een taken by Government so far; nd

(e) what are the details of the producers who have been booked for vercharging of bulk drugs and formulations during 1992?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (c) The names of ulk drugs in respect of which complaints of alleged overcharling of prices received during 1992 are given in he statement attached. (*See* below)

(b), (d) and (e) As and when any omplaint of alleged overcharging of ulk drugs and formulations is received, the same is forwarded to the oncerned State Drug Control Administration for investigation and the ompanies concerned are also asked explain its position. In case the acts are found to be correct after he investigation, by the State Drug ontroller further action under DPCO, 987 as well as under the Essential ommodities Act, 1955, as the case ay be, is initiated.

Statement

r. No.	Name of the Bulk Drug
1.	Vitamin C Plain
2.	Vitamin C Coated
3.	Sodium Ascorbates
4.	Prednisolone
5.	Rifampicin
6.	Erythromycin Stearate
7.	Ampicillin Trihydrate
8.	Trimethoprim
9.	Metronidazole
10.	Metronidazole Benzoate
11.	Pyrazinamide
12.	Di Ethyl Carbamazine Citrate
13.	Ethambutol Hcl
14.	Claxacillin Sodium (Oral Grade)
15.	Chloroquine Phosphate
16.	Sulphamethoxole
17.	Tetracycline Hcl
18.	Analgin
19.	Amoxycillin Trihydrate
20.	Cephalexin.

Ceiling prices of salbutamol formulations

4589. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that M|s. Glaxo is not following the ceiling prices of Salbutamol formulations;

(b) what are the details of formulations based on Salbutamol being marketed by M|s. Glaxo and what are their present price;

(c) whether it is a fact that M|s. Glaxo is selling Salbutamol Inhaler without price approval;

(d) if so, what is the approved price and at what price it is being marketed at present;

(e) whether it is a fact that M|s. Glaxo is marketing number of other formulations without price approval;

(f) if so, what are the prices of all such formulations as approved by Government and the prices at which the company is selling and since when;

(g) whether it is a fact that M|s. Glaxo is marketing number of finished medicines without price approval manufactured by small scale units; and

(h) if so, what are the names of those products?

THE MINISTER OF STATE IN AND FERTILIZERS (SHRI CHINTA AND FERTILIZERS (SHRI CHNTA MOHAN): (a) and (b) A Statement